Clinical Trials Arena August 30, 2024
The French government funds will support clinical development for T cell-activating monoclonal antibody and another project.
ImCheck Therapeutics has received €20.18m ($22.35m) in non-dilutive funding from the French government to advance its pipeline.
The funds were disbursed as part of the “i-Démo” call for projects under the France 2030 Plan operated by Bpifrance on behalf of the French government. The public capital will be used to advance ImCheck’s clinical pipeline consisting of a T cell-activating monoclonal antibody and an infectious disease therapy.
The French company’s lead candidate is ICT01, a pathogen-agnostic γ9δ2 T cell-activating monoclonal antibody targeting BTN2A, also known as CD277. It is being evaluated in multiple solid tumours and blood cancer indications in Phase I/IIa trials.
The company...
Today's Sponsors
Today's Sponsor